Genomtec S.A. (WSE:GMT)

Market Cap	71.11M -28.8%
Revenue (ttm)	15.00K +1,400.0%
Net Income	-11.01M
EPS	-0.75
Shares Out	15.06M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,663
Average Volume	20,922
Open	4.830
Previous Close	4.830
Day's Range	4.710 - 4.830
52-Week Range	3.245 - 7.700
Beta	0.29
RSI	54.69
Earnings Date	Apr 30, 2026

About Genomtec

Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company’s flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology. In addition, ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2008
• Employees: 26
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: GMT

Financial Performance

In 2024, Genomtec's revenue was 1,000, a change of 0.00% compared to the previous year's 1,000. Losses were -11.21 million, 24.4% more than in 2023.